ArticleKidney medicine2026
Renin-Angiotensin System Inhibitors in Patients With Nonproteinuric Chronic Kidney Disease and Kidney Outcomes: Findings From the CRIC Study.
Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Renin-angiotensin system inhibitor use and cardio-renal outcomes in non-proteinuric chronic kidney disease: a post-hoc analysis of the Frontier of Renal Outcome Modification-Japan study.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale & Objective: The kidney-protective benefits of renin-angiotensin system inhibitors (RASIs; ie, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers) in nonproteinuric chronic kidney disease (CKD) are unclear. We aimed to evaluate kidney outcomes in adults with nonproteinuric CKD treated with RASIs versus other antihypertensive medications. Study Design: Using data from the Chronic Renal Insufficiency Cohort study, a prospective cohort study, we evaluated the association of RASI use with kidney outcomes and survival. Secondary analyses included censoring with drug discontinuation and a time-updated RASI approach (ie, cumulative exposure). Setting & Participants: Individuals with <0.5 g/d of proteinuria (via 24-hour urine collection or spot test) on ≥1 antihypertensive medication. Participants with heart failure were excluded. Exposure: Patient-reported use of RASIs versus non-RASI antihypertensive medication. Outcomes: (1) CKD progression (halving of estimated glomerular filtration rate, dialysis, or transplant) and (2) all-cause mortality. Analytical Approach: Inverse probability of treatment weighting and Cox proportional hazards modeling; marginal structural models. Results: Among the 2,664 participants, the mean age was 62 years, 46% were female, and the mean estimated glomerular filtration rate was 50 mL/min/1.73 m Limitations: Residual confounding cannot be ruled out. Medication use was patient-reported, increasing the potential for misclassification. Conclusions: For people with nonproteinuric CKD, RASIs may not be kidney-protective but may still confer a mortality benefit for hypertension management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.